Literature DB >> 11479743

Galactosemia: deletion in the 5' upstream region of the GALT gene reduces promoter efficiency.

M Trbusek1, H Francová, L Kozák.   

Abstract

Galactosemia is a metabolic disorder caused by a defect in the galactose-1-phosphate uridyltransferase (GALT) enzyme. In previous studies, we have shown that the presence of a deletion in the 5' upstream (promoter) region of the GALT gene is associated with the Duarte (D2) allele. In the present study, by using a promoter fusion assay we provide direct evidence that a GTCA deletion located in position -119/-116 of the GALT gene (considered in relation to the translational start site) decreases transcription of a reporter gene to about 55% compared with a normal "healthy" promoter transfected into human hepatocyte HepG2 cells. This result coincides well with previously published biochemical data showing 50% GALT-gene activity in Duarte (D2) galactosemia patients. By transfecting the same promoters (normal and deleted) into mouse NIH/3T3 cells, we show that the GTCA motif in the promoter region of the GALT gene was conserved throughout evolution. We conclude that the -119/-116delGTCA promoter mutation is a crucial factor in reduction of Duarte allele enzyme activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479743     DOI: 10.1007/s004390100540

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  8 in total

1.  Phenotype-Genotype Discrepancy Due to a 5.5-kb Deletion in the GALT Gene.

Authors:  Ariadna González-del Angel; José Velázquez-Aragón; Miguel A Alcántara-Ortigoza; Marcela Vela-Amieva; Nancy Hernández-Martínez
Journal:  JIMD Rep       Date:  2011-09-06

2.  Duarte galactose-1-phosphate uridyl transferase genotypes are not associated with ovarian cancer risk.

Authors:  Melissa A Merritt; Joanne Kotsopoulos; Daniel W Cramer; Susan E Hankinson; Kathryn L Terry; Shelley S Tworoger
Journal:  Fertil Steril       Date:  2012-06-29       Impact factor: 7.329

3.  Newborn screening for galactosemia in the United States: looking back, looking around, and looking ahead.

Authors:  Brook M Pyhtila; Kelly A Shaw; Samantha E Neumann; Judith L Fridovich-Keil
Journal:  JIMD Rep       Date:  2014-04-10

4.  Low allelic heterogeneity in a sample of Mexican patients with classical galactosaemia.

Authors:  J Velázquez-Aragón; M A Alcántara-Ortigoza; M Vela-Amieva; S Monroy; V Martínez-Cruz; C Todd-Quiñones; A González-del Angel
Journal:  J Inherit Metab Dis       Date:  2008-10-29       Impact factor: 4.982

Review 5.  Dominant versus recessive: molecular mechanisms in metabolic disease.

Authors:  Johannes Zschocke
Journal:  J Inherit Metab Dis       Date:  2008-10-21       Impact factor: 4.982

6.  Functional and structural impact of the most prevalent missense mutations in classic galactosemia.

Authors:  Ana I Coelho; Matilde Trabuco; Ruben Ramos; Maria João Silva; Isabel Tavares de Almeida; Paula Leandro; Isabel Rivera; João B Vicente
Journal:  Mol Genet Genomic Med       Date:  2014-06-23       Impact factor: 2.183

Review 7.  Sweet and sour: an update on classic galactosemia.

Authors:  Ana I Coelho; M Estela Rubio-Gozalbo; João B Vicente; Isabel Rivera
Journal:  J Inherit Metab Dis       Date:  2017-03-09       Impact factor: 4.982

8.  Origins, distribution and expression of the Duarte-2 (D2) allele of galactose-1-phosphate uridylyltransferase.

Authors:  Amanda E Carney; Rebecca D Sanders; Kerry R Garza; Lee Anne McGaha; Lora J H Bean; Bradford W Coffee; James W Thomas; David J Cutler; Natalie L Kurtkaya; Judith L Fridovich-Keil
Journal:  Hum Mol Genet       Date:  2009-02-18       Impact factor: 6.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.